Legend Biotech Corporation (LEGN) Stock Price & How to Invest

Legend Biotech is a global cell-therapy company best known for CARVYKTI (ciltacabtagene autoleucel, or cilta-cel), a one-time BCMA-directed CAR-T treatment for relapsed or refractory multiple myeloma. It develops and commercializes CARVYKTI in a 50/50 profit-and-cost-sharing collaboration with Johnson & Johnson, so Legend's reported revenue shows up largely as collaboration and license income rather than direct product sales. The company also runs an earlier-stage pipeline of other cell therapies and solid-tumor programs, but CARVYKTI drives essentially all of the current commercial narrative.

The investment picture is a scaling-into-profitability story. CARVYKTI reached roughly $1.9 billion in global net trade sales in 2025 and grew about 62 percent year over year in the first quarter of 2026, helped by earlier-line use and expanded manufacturing across more than 300 treatment sites. Legend has been narrowing its losses toward adjusted breakeven while holding a sizable cash cushion, but it remains dependent on one franchise, on J&J as its commercial partner, and on a competitive multiple-myeloma market. The stock trades as a high-multiple growth biotech, so results and the pace toward sustained profit matter a great deal.

Legend's value is heavily concentrated in one product, CARVYKTI, and in one partner, Johnson & Johnson, which shares profits and controls much of the commercial engine. The multiple-myeloma market is increasingly crowded, with competing CAR-T therapies like Bristol Myers Squibb's Abecma and off-the-shelf BCMA bispecific antibodies such as J&J's Tecvayli and Pfizer's Elrexfio that avoid CAR-T's manufacturing and logistics burden. CAR-T therapies also carry serious safety considerations and manufacturing and capacity constraints that can cap growth. The company is only near breakeven and still posts losses, so any sales miss, pricing pressure, or safety signal can move the stock sharply. As a China-founded, US-listed ADR, it also carries geopolitical, supply-chain, and regulatory exposure that pure-play US biotechs do not.

15 analysts publish price targets on LEGN, averaging $52.10 against a $18.55 price as of August 2026, or +180.9%. The published targets run from $27.00 to $80.00, a wide spread, and the ratings split 11 buy, 4 hold, 0 sell. Over the last six months there have been 4 raises and 4 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full LEGN forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Legend Biotech Corporation. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. CARVYKTI commercial ramp. CARVYKTI net trade sales reached about $1.9 billion in 2025 and rose roughly 62 percent year over year in Q1 2026, with ex-US sales growing far faster than US sales off a smaller base. The most optimistic published target, $80.00, assumes this works close to its best case.

The case against. Legend's value is heavily concentrated in one product, CARVYKTI, and in one partner, Johnson & Johnson, which shares profits and controls much of the commercial engine. The most pessimistic target, $27.00, is roughly what LEGN is worth if this bites instead.

Read the full bull and bear case on LEGN, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Legend Biotech Corporation's investor relations page or your broker.

• Revenue (TTM, collaboration/license): ~$1.1B
• CARVYKTI net trade sales (FY2025, global): ~$1.9B
• Q1 2026 total revenue: ~$305M
• FY2025 adjusted net loss: ~$33M
• Cash & time deposits (Q1 2026): ~$835M
• Market cap: ~$5.8B

LEGN trades as a high-multiple growth biotech whose revenue is recognized mainly as collaboration and license income under the J&J profit split, distinct from CARVYKTI's roughly $1.9 billion in 2025 global net trade sales. The company is approaching adjusted breakeven while still reporting losses, so the valuation reflects expectations for continued CARVYKTI growth rather than current earnings. Wall Street price targets vary widely, underscoring how much hinges on the pace of the ramp.

Other names that sit close to LEGN: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get LEGN exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so LEGN sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where LEGN fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

LEGN is effectively a one-product CAR-T story riding CARVYKTI's ramp with J&J, so the payoff and the risk both hinge on that single franchise.

Whether LEGN is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is LEGN a buy or a sell?, and where the stock could go from here in the LEGN stock forecast.

For income investors, whether LEGN pays a dividend and how the payout looks is covered in does LEGN pay a dividend? And to weigh LEGN against a peer, read the full side-by-side comparisons: LEGN vs CAR and LEGN vs BMY.